SIGA

Company Overview

A Leader in Global Health & Infectious Diseases

July 2024

Forward Looking Statements

The statements made in this presentation may include forward-looking statements regarding the treatment of smallpox and other orthopoxvirus infections, the development and attributes of SIGA Technologies, Inc. ("SIGA") products, and the future operations, opportunities or financial performance of SIGA. Although we believe that the expectations contained in this presentation are reasonable, these forward-looking statements are only estimations based upon the information available to SIGA as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our forward-looking statements, whether as a result of new information, future events or otherwise. Thus, the forward-looking statements herein involve known and unknown risks and uncertainties and other important factors such that actual future operations, opportunities or financial performance may differ materially from these forward-looking statements.

Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof. All forward-looking statements contained herein are qualified in their entirety by the foregoing cautionary statements.

For a more detailed discussion of our risks, see the Risk Factors section in SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC and our other filings with the SEC, including our most recent Quarterly Report, all of which are available on our website, www.siga.com.

Contents

SIGA at a Glance

Stellar Revenue Generation
>$1bn of Procurement Contracts from 10+ years Working with Governments

TPOXX
A Foundational Franchise & Trusted Treatment for Smallpox & Mpox[2]

Strong Expertise
Infectious Disease, Public Health, and Government Contracting

25+ Countries
Where Products Are Sold

Revenues by Geography[1]



SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focused on providing **solutions** for **unmet needs** in emerging **infectious diseases**. The company is headquartered in New York City, with research and development operations in Corvallis, Oregon.

(1) From 2020 – 2023
(2) Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus; TPOXX is approved by the U.S. FDA and Health Canada for the treatment of smallpox. TPOXX is not approved as a treatment for mpox in the U.S.

SIGA is a Leader in Global Health and Infectious Disease

Fully Integrated Infectious Disease Capabilities

Highly profitable, commercial stage pharmaceutical company operating within infectious disease and health security

Experienced senior management team with **deep expertise in commercial, antiviral R&D, and government contracting & relations**

Fully integrated, **U.S.-based operational supply chain**

Foundation for Continued Attractive Growth

Near term opportunities for TPOXX indication expansions (mpox in the U.S., post-exposure prophylaxis "PEP", pediatric formulation)

Geographic expansion ex-U.S., including Canada, Europe, ROW

Able to leverage antiviral and strong government procurement capabilities to move into complementary therapeutic areas with similar points of patient care

Attractive inorganic growth opportunities to expand into adjacencies and therapeutic areas with scientific and commercial synergies

Leading TPOXX Product Platform

Lead product is oral TPOXX, an antiviral drug for treating smallpox (FDA approved in 2018) and orthopox (EMA approved in 2022)

Only **one of two approved antivirals for orthopox treatment**; distinct mechanism of action supports strong efficacy and safety profile

Track record of securing multi-year government awards across multiple agencies

Best-in-Class Financial Performance

Realized **~$500 mm of TPOXX revenue with robust gross margins** in 2020 – 2023

Highly profitable company with **~$300 mm in pre-tax operating income** in 2020 – 2023

Robust balance sheet and cash flow with **minimal CAPEX and no debt**

Executing on our Strategy for Growth



Comprehensive Capabilities Provide Strong Foundation

Entrenched relationships with key government agencies

Positive track-record of contract performance



Proven R&D capabilities

Close coordination with government agencies to jointly develop high-impact therapies

Ongoing label expansions for TPOXX

Fully integrated U.S. end-to-end supply chain network

Experienced Leadership in Infectious Diseases and Government Relations

Diem Nguyen, PhD, MBA
Chief Executive Officer

Visionary: Spearheaded $11 bn revenue global operating units that generated one third of Pfizer's annual profit

Dan Luckshire
Chief Financial Officer

Operational Excellence and Financial Integrity Leader: Demonstrated leadership in finance, investment banking, and commercial operations

Jay Varma, MD
Chief Medical Officer

Public Health Guru: Led public health programs and outbreak responses in Asia, Africa, and US that saved hundreds of millions of lives

Dennis Hruby
Chief Scientific Officer

World Renowned Infectious Disease Researcher: Led the discovery, development, and approval of TPOXX

Larry Miller
General Counsel

Strategic Partner: Experienced lawyer with breadth of capabilities in corporate law, M&A, and public companies

Tove Bolken
SVP, Operations and Chief Supply Chain Officer

Flawless Operator: Managed manufacturing, process development and supply chain oversight

Persistent, Durable Financial Performance Over Time

Revenues ($mm)



Pre-tax Operating Income ($mm)



Capital Management[1] ($mm)



Averages for 2020 – 2023 ($mm)



(1) Includes dividends and share repurchases

Era of Emerging Viruses

Emergence of New Viruses Threaten Health Security



Orthopox Threatens Global Health through Natural Occurrence or Potential Bioweapon Warfare



Smallpox Remains a Significant Threat Today

Highly contagious and fatal disease in susceptible population



2022 Mpox Global Outbreak Demonstrates the Need for Orthopox Antiviral Therapies

2022 Mpox Outbreak

Mpox belongs to orthopox family

Lesions are extremely painful with weeks to months of recovery

In 2022, global mpox outbreak impacted >90,000 cases

Case fatality >160 deaths

Rapid Containment Response

TPOXX quickly identified as a potentially effective treatment

In the U.S., the CDC distributed 80,000+ bottles of oral TPOXX and 13,000+ vials of IV TPOXX under EAU

Ongoing Threat

CDC and WHO concerned mpox[(1)] is a forewarning of graver threats

Ongoing outbreak in the DRC with 19,000+ cases and 900 deaths since January 2023

Caused by Clade 1 with case-fatality far greater than the 2022 strain (~5-10%)

CDC issued a health alert in December 2023

FDA, NIH and CDC have been Working to Support the Expanded Access Use of TPOXX

(1) TPOXX is approved for mpox in Europe

TPOXX: A Differentiated Product

Orthopox Family Encompasses a Spectrum of Diverse Diseases

Orthopoxvirus infections can cause a range of febrile rash illnesses in humans, from fairly benign, localized skin infections to severe systemic infections. There are four orthopoxvirus species known to cause human disease:

VARIOLA VIRUS (SMALLPOX)

Causative agent of smallpox; TPOXX received FDA approval for treatment in 2018.

COWPOX VIRUS

Human cowpox virus infection is classically associated with occupational exposure to cattle; however, other animals, including rats, pet cats, and zoo and circus elephants, have been implicated. Infection can be lethal in immunocompromised individuals.

MPOX VIRUS

Mpox virus causes intermittent human infections, primarily in Central and West Africa, although isolated outbreaks have been identified in the United States and Sudan; the disease is very similar to smallpox. Case fatality rates range from <1% to >10% depending on virus clade.

VACCINIA VIRUS

Vaccinia virus is used as the smallpox vaccine and some cancer therapies in development. It causes sporadic disease in those immunized/treated, contacts of those immunized/treated, and laboratory workers. Infection can be lethal in immunocompromised individuals.

TPOXX is a Clinically Differentiated Medical Countermeasure

antivirals ← → vaccines

TPOXX
Tecovirimat SIGA
(ST-246/tecovirimat)

- First FDA-approved drug with indication for treatment of smallpox
- Targets VP37 protein of orthopoxviruses, preventing envelopment and release of virions
- **Activity against all orthopoxviruses** tested in vitro (nanomolar concentrations) and in all animal models
- **Well-tolerated** in human clinical trials

TEMBEXA®
(CMX001/brincidofovir)

- FDA-approved drug with indication for treatment of smallpox
- Targets E9L DNA polymerase of orthopoxviruses and inhibits DNA synthesis
- Exhibits antiviral activity against orthopoxviruses tested in vitro and two animal models, as well as against other DNA viruses
- **Black box warning due to increased mortality** with prolonged use and various toxicities

ACAM2000®
(plus other replicating vaccinia vaccine)

- Live vaccinia virus smallpox vaccine
- May cause **serious adverse reactions** (including death), especially in immunocompromised and those with eczema or atopic dermatitis
- 20-25% of the population would be contraindicated to receiving the vaccine
- Ineffective if given >4 days post-exposure

IMVANEX/IMVAMUNE/
JYNNEOS® (MVA-BN®)

- Modified vaccinia virus Ankara vaccine approved for prevention of smallpox and monkeypox disease in adults 18 years of age
- Does not replicate in mammalian cells
- Well-tolerated but requires two doses administered 28 days apart for full efficacy

TPOXX Demonstrates Strong Safety and Efficacy in Humans

Note: TPOXX/Tecovirimat SIGA approved by the U.S., Canada, EU, and UK; TEMBEXA approved by the U.S. and Canada; ACAM2000 approved by the U.S., Australia, and Singapore; and MVA-BN approved by the U.S., Canada, and EU.

Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX

	2011 TPOXX CONTRACT	2018 TPOXX CONTRACT
PROCUREMENT DURATION	2011-2018	2018-current
KEY AGENCY INVOLVED	U.S. Biomedical Advanced Research and Dev. Authority ("BARDA")	U.S. Biomedical Advanced Research and Dev. Authority ("BARDA")
CONTRACT VALUE	▪ $461 mm total procurement contract value ▪ $461 mm fully delivered	▪ $546 mm total procurement contract value ▪ $408 mm ordered; $341 mm delivered as of 12/31/2023; $138 mm outstanding options

New Contract with Administration for Strategic Preparedness & Response (ASPR) for U.S. National Stockpile Targeted in 2024

SIGA

Growth Strategy

Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications

TPOXX Franchise is the Foundation for Expansion with over $1bn in Multi-Year Contracts

PEP Program
(post-exposure prophylaxis)

Addresses **time gap** between exposure and signs of clinical infection

Studies are supportive of the use of TPOXX in PEP to **reduce morbidity and mortality**

Targeting FDA **submission** in 2025

Mpox Program

Critical to provide in countries where not approved for this virus

Supporting 5 randomized controlled **trials** (RCT) and multiple observational studies

Working with government sponsors and FDA on **pathway to submission**

Pediatric Program

Important program to protect the **pediatric population**

Completed trial that demonstrates **equivalence of drug exposure** in volunteers (oral vs liquid formulation)

Designing **clinical program** to support regulatory filing

Selected a **manufacturer** to prepare clinical supplies

TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox



PEP program has received $27 mm of development funding from U.S. Department of Defense

TPOXX (tecovirimat) Clinical Trials for Mpox

PLATINUM-CAN RCT (tecovirimat vs. placebo) – McGill University: Canada *Enrollment ongoing*

PLATINUM-UK RCT (tecovirimat vs. placebo) – University of Oxford: UK
Closed to enrollment

EPOXI RCT (tecovirimat vs. placebo) – University Medical Center Utrecht: Europe
Not yet recruiting

MOSAIC Observational (treated and not treated with tecovirimat or other antivirals) – University of Oxford: Europe
Enrollment complete

TPOXX Expanded Access for Treatment of Non-Variola Orthopoxvirus Infections in Adults and Children (treated with tecovirimat) – CDC: U.S.
Ongoing; from May 27, 2022 – August 7, 2023, 7,653 patients were prescribed or treated with tecovirimat



MEURI Observational (treated and not treated with tecovirimat – WHO: Global
Enrollment ongoing

Expanded Access (treated with tecovirimat)) – University of Oxford: CAR
Enrollment ongoing

A5418/STOMP RCT (tecovirimat vs. placebo) – NIAID/DAIDS: Argentina, Brazil, Japan, Mexico, Peru, Puerto Rico, Thailand , U.S.
Enrollment ongoing

PALM007 RCT (tecovirimat vs. placebo) – NIAID/INRB: DRC
Enrollment ongoing

UNITY RCT (tecovirimat vs. placebo) – ANRS: Argentina, Brazil, Switzerland
Enrollment ongoing

MOSA RCT (tecovirimat vs. placebo) – PANTHER: Benin, Cameroun, Congo, DRC, Ghana Liberia, Nigeria, Mali, RCA, Sudan
Not yet recruiting

SIGA

Cultivate Partnerships to Expand Global Access

Collaborating with Governments and Other Partners on Heath Security is Best-in-Class Core Competency

Strong Long-Standing Partnerships

- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Biomedical Advanced Research and Development Authority (BARDA)
- Stockpiling Lifesaving Medical Countermeasures
- U.S. Department of Defense

Proven Track Record

- Secured funding for over $1 bn in multi-year contracts for TPOXX
- Sold +$100 mm of TPOXX to more than 25 countries since 2020

Common Goal of Global Health Security

- Shared understanding that with the current geopolitical environment, the risk of a rogue actor or nation weaponizing a virus has increased
- Clear recognition of the need to stockpile TPOXX and other critical medicines in the event of an outbreak to quickly contain the impact

Financial Summary

Strong Financial Performance

1 U.S. Government Orders under Current Contracts

- ~$400 mm of TPOXX (1.2 mm courses) ordered for SNS over the past 4 years
- ~$11 mm of oral TPOXX ordered by the Department of Defense in 2023

2 International Orders

- Over $100 mm of international oral TPOXX ordered by more than 25 countries since 2020

3 Financial Results

- Cumulative pre-tax operating income of ~$300 mm for the 2020 – 2023 time period
- 2023 product sales of $131 mm and pre-tax operating income of $84 mm

($ in millions)	FY 2020	FY 2021	FY 2022	FY 2023
Product Sales				
Oral TPOXX (U.S. Government)	$113	$113	$7	$110
Oral TPOXX (International)	$2	$13	$71	$21
IV TPOXX	---	---	$7	---
Total Product Sales	**$115**	**$127**	**$87**	**$131**
Pre-Tax Operating Income	**$85**	**$89**	**$43**	**$84**
Net Income	**$56**	**$69**	**$34**	**$68**

Key Takeaways

Leveraging Infectious Disease Foundation	Expanding Successful TPOXX Franchise	Driving Organic Growth Initiatives	Expanding Platform with Inorganic Growth	Delivering Robust Financial Performance
Leading health security and infectious disease pharmaceutical company with a fully integrated business with commercial, R&D, manufacturing and supply, and government relations capabilities	Proven track record of success having received > $1 bn in government contracts and delivered to governments around the globe	Multiple organic growth opportunities across both label expansion and geographic expansion	Attractive opportunities to expand into adjacencies and therapeutic areas with scientific and commercial synergies	Strong financial growth over time, generating significant cash flow for the company and shareholders

We are Well Positioned for Growth and Attractive Returns Over Time